In the Asian region Vitrolife faces a challenging period. This challenge is mainly related to very challenging comps, and it has not been made easier due to some structural regional changes and the fact that Asia is a high-margin region for Vitrolife. At the same time, Vitrolife continues to invest in commercial execution, especially in the US market. Realistically, the initial organic growth will be modest, and the time to reach the target of >10% will take longer.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/